1‐(3‐ethylcyclobutyl)ethanone | 56335-71-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1‐(3‐ethylcyclobutyl)ethanone
• 英文别名: 1-Acetyl-3-ethylcyclobutan；1-acetyl-3-ethylcyclobutane；Ethanone, 1-(3-ethylcyclobutyl)-；1-(3-ethylcyclobutyl)ethanone
• CAS: 56335-71-8
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: CFXVQAFALKCPFF-UHFFFAOYSA-N

物化性质

• 沸点：
  173.2±8.0 °C(Predicted)
• 密度：
  0.902±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1‐(3‐ethylcyclobutyl)ethanone 、 间氯过氧苯甲酸 在 ice 、 氯仿 、 disodium;dioxido-oxo-sulfanylidene-λ6-sulfane 、 disodium;carbonate 、 Brine 、 Sodium sulfate-III 作用下， 以 氯仿 为溶剂， 反应 120.0h， 以to afford 3.55 g of 1-acetoxy-3-ethylcyclobutane的产率得到1-Acetoxy-3-ethyl-cyclobutan
  参考文献：
  名称：

  15-Deoxy-16-hydroxy prostaglandins for producing bronchodilation

  摘要：

  具有结构式##STR1##的PGE.sub.1类似物，其中J为R-羟甲基或S-羟甲基；R.sub.1为氢；R.sub.2为氢或与R.sub.4一起形成2至3个碳原子的亚甲基链，形成5至6个碳原子的环烷基；R.sub.3为氢或甲基，或与R.sub.4一起形成2至5个碳原子的亚甲基或较低烷基化亚甲基链，形成4至7个碳原子的环烷基或较低烷基化环烷基，或与R.sub.4一起形成有公式的双环烷基或双环烯基基团：##STR2##形成双环烷基或双环烯基化合物，其中m和n是整数，值为0至3，p是整数，值为0至4，q是整数，值为1至4，其中此类双环烯基的双键在m、n、p或q桥上；R.sub.4为氢或甲基，或与R.sub.2或R.sub.3一起形成上述定义的环烷基、双环烷基或双环烯基，或与R.sub.5一起形成3至5个碳原子的亚甲基链，形成4至6个碳原子的环烷基；R.sub.5选自由由1至3个碳原子的直链烷基或与R.sub.4形成上述定义的环烷基的群；R.sub.6为氢或由1至3个碳原子的直链烷基。还公开了上述结构中仅限于R.sub.2、R.sub.3、R.sub.4和R.sub.5中的两个形成环烷基、较低烷基化环烷基、双环烷基或双环烯基的PGE.sub.1酯类似物。这些前列腺素类似物在体内具有选择性地产生支气管扩张和减少胃分泌的作用。还公开了制备这些类似物和合成这些类似物所需的起始材料的方法。

  公开号：

  US04415592A1
• 作为产物：
  描述：

  3-乙基环丁烷羧酸 、 甲基锂 以 乙醚 为溶剂， 生成 1‐(3‐ethylcyclobutyl)ethanone
  参考文献：
  名称：

  Preparation of 15-deoxy-16-hydroxyprostaglandins

  摘要：

  具有结构式##STR1##的PGE.sub.1的类似物，其中J是R-羟甲亚甲基或S-羟甲亚甲基；R.sub.1是氢；R.sub.2是氢或与R.sub.4一起是2到3个碳原子的亚甲基链，形成包括5到6个碳原子的环烷基；R.sub.3是氢或甲基，或与R.sub.4一起是2到5个碳原子的亚甲基或低烷基化亚甲基链，形成包括4到7个碳原子的环烷基或低烷基化环烷基，或与R.sub.4一起是具有式子的双环烷基或双环烯基基团：##STR2##形成双环烷基或双环烯基化合物，其中M和N是具有值从0到3的整数，P是具有值从0到4的整数，Q是具有值从1到4的整数，且此类双环烯基的双键位于M、N、P或Q桥上；R.sub.4是氢或甲基，或与R.sub.2或R.sub.3一起形成如上定义的环烷基或双环烷基或双环烯基，或与R.sub.5一起是3到5个碳原子的亚甲基链，形成包括4到6个碳原子的环烷基；R.sub.5选自由氢、具有1到3个碳原子的直链烷基或与R.sub.4一起形成如上定义的环烷基；R.sub.6是氢或具有1到3个碳原子的直链烷基。上述结构的Pge.sub.1酯类似物，限于其中两个R.sub.2、R.sub.3、R.sub.4和R.sub.5形成环烷基、低烷基化环烷基、双环烷基或双环烯基的结构也被披露。这些前列腺素类似物在体内选择性地产生支气管扩张并减少胃分泌。还披露了制备这些类似物以及合成这些类似物所需的起始物料的方法。

  公开号：

  US04132738A1

文献信息

• 15-Deoxy-16-hydroxy prostaglandins for producing bronchodilation
  申请人：Miles Laboratories, Inc.

  公开号：US04415592A1

  公开（公告）日：1983-11-15

  Analogues of PGE.sub.1 having the structural formula, ##STR1## in which J is R-hydroxymethylene or S-hydroxymethylene; R.sub.1 is hydrogen; R.sub.2 is hydrogen or together with R.sub.4 is a methylene chain of 2 to 3 carbon atoms such that a cycloalkyl of 5 to 6 carbon atoms inclusive is formed; R.sub.3 is hydrogen or methyl, or together with R.sub.4 is a methylene or a lower alkylated methylene chain of 2 to 5 carbon atoms such that a cycloalkyl or a lower alkylated cycloalkyl of 4 to 7 carbon atoms inclusive is formed, or together with R.sub.4 is bicycloalkyl or bicycloalkenyl moiety having the formula: ##STR2## such that a bicycloalkyl or bicycloalkenyl compound is formed, wherein m and n are integers having a value from 0 to 3, p is an integer having a value from 0 to 4 and q is an integer having a value of from 1 to 4 and wherein the double bond of such bicycloalkenyl is in the m, n, p, or q bridge; R.sub.4 is hydrogen or methyl or together with R.sub.2 or R.sub.3 forms a cycloalkyl or bicycloalkyl or bicycloalkenyl as defined above, or together with R.sub.5 is a methylene chain of 3 to 5 carbon atoms such that a cycloalkyl of 4 to 6 carbon atoms inclusive is formed; R.sub.5 is selected from the group consisting of hydrogen, straight-chain alkyl having from 1 to 3 carbon atoms or together with R.sub.4 forms a cycloalkyl as defined above; and R.sub.6 is hydrogen or straight-chain alkyl having from 1 to 3 carbon atoms are disclosed. PGE.sub.1 ester analogues of the above formula, limited to the structures wherein two of R.sub.2, R.sub.3, R.sub.4 and R.sub.5 form a cycloalkyl, lower alkylated cycloalkyl, bicycloalkyl or bicycloalkenyl are also disclosed. The prostaglandin analogues selectively produce bronchodilation and decrease gastric secretion in vivo. Methods of preparing the analogues and starting materials required in the synthesis of the analogues are also disclosed.

  具有结构式##STR1##的PGE.sub.1类似物，其中J为R-羟甲基或S-羟甲基；R.sub.1为氢；R.sub.2为氢或与R.sub.4一起形成2至3个碳原子的亚甲基链，形成5至6个碳原子的环烷基；R.sub.3为氢或甲基，或与R.sub.4一起形成2至5个碳原子的亚甲基或较低烷基化亚甲基链，形成4至7个碳原子的环烷基或较低烷基化环烷基，或与R.sub.4一起形成有公式的双环烷基或双环烯基基团：##STR2##形成双环烷基或双环烯基化合物，其中m和n是整数，值为0至3，p是整数，值为0至4，q是整数，值为1至4，其中此类双环烯基的双键在m、n、p或q桥上；R.sub.4为氢或甲基，或与R.sub.2或R.sub.3一起形成上述定义的环烷基、双环烷基或双环烯基，或与R.sub.5一起形成3至5个碳原子的亚甲基链，形成4至6个碳原子的环烷基；R.sub.5选自由由1至3个碳原子的直链烷基或与R.sub.4形成上述定义的环烷基的群；R.sub.6为氢或由1至3个碳原子的直链烷基。还公开了上述结构中仅限于R.sub.2、R.sub.3、R.sub.4和R.sub.5中的两个形成环烷基、较低烷基化环烷基、双环烷基或双环烯基的PGE.sub.1酯类似物。这些前列腺素类似物在体内具有选择性地产生支气管扩张和减少胃分泌的作用。还公开了制备这些类似物和合成这些类似物所需的起始材料的方法。
• Therapeutic method for producing bronchodilation by administration of
  申请人：Miles Laboratories, Inc.

  公开号：US04742080A1

  公开（公告）日：1988-05-03

  A therapeutic method for producing bronchodilation in an individual for whom such therapy is indicated is disclosed. The method comprises administering to said individual an effective bronchodilation amount of certain derivatives of 15-deoxy-16-hydroxy-prostaglandin E.sub.1 esters.

  本发明公开了一种治疗方法，用于在需要这种治疗的个体中产生支气管扩张。该方法包括向该个体施用一定量的15-去氧-16-羟基-前列腺 E.sub.1 酯的某些衍生物，以达到有效的支气管扩张作用。
• 15-Deoxy-16-hydroxy prostaglandins
  申请人：Miles Laboratories, Inc.

  公开号：US04275224A1

  公开（公告）日：1981-06-23

  Analogues of PGE.sub.1 having the structural formula, ##STR1## in which J is R-hydroxymethylene or S-hydroxymethylene; R.sub.1 is hydrogen; R.sub.2 is hydrogen or together with R.sub.4 is a methylene chain of 2 to 3 carbon atoms such that a cycloalkyl of 5 to 6 carbon atoms inclusive is formed; R.sub.3 is hydrogen or methyl, or together with R.sub.4 is a methylene or a lower alkylated methylene chain of 2 to 5 carbon atoms such that a cycloalkyl or a lower alkylated cycloalkyl of 4 to 7 carbon atoms inclusive is formed, or together with R.sub.4 is bicycloalkyl or bicycloalkenyl moiety having the formula: ##STR2## such that a bicycloalkyl or bicycloalkenyl compound is formed, wherein m and n are integers having a value from 0 to 3, p is an integer having a value from 0 to 4 and q is an integer having a value of from 1 to 4 and wherein the double bond of such bicycloalkenyl is in the m, n, p, or q bridge; R.sub.4 is hydrogen or methyl or together with R.sub.2 or R.sub.3 forms a cycloalkyl or bicycloalkyl or bicycloalkenyl as defined above, or together with R.sub.5 is a methylene chain of 3 to 5 carbon atoms such that a cycloalkyl of 4 to 6 carbon atoms inclusive is formed; R.sub.5 is selected from the group consisting of hydrogen, straight-chain alkyl having from 1 to 3 carbon atoms or together with R.sub.4 forms a cycloalkyl as defined above; and R.sub.6 is hydrogen or straight-chain alkyl having from 1 to 3 carbon atoms are disclosed. PGE.sub.1 ester analogues of the above formula, limited to the structures wherein two of R.sub.2, R.sub.3, R.sub.4 and R.sub.5 form a cycloalkyl, lower alkylated cycloalkyl, bicycloalkyl or bicycloalkenyl are also disclosed. The prostaglandin analogues selectively produce bronchodilation and decrease gastric secretion in vivo. Methods of preparing the analogues and starting materials required in the synthesis of the analogues are also disclosed.

  具有结构式##STR1##的PGE.sub.1类似物，其中J为R-羟甲基或S-羟甲基；R.sub.1为氢；R.sub.2为氢或与R.sub.4一起形成2至3个碳原子的亚甲基链，从而形成包括5至6个碳原子的环烷基；R.sub.3为氢或甲基，或与R.sub.4一起形成2至5个碳原子的亚甲基或较低烷基化亚甲基链，从而形成包括4至7个碳原子的环烷基或较低烷基化环烷基，或与R.sub.4一起形成具有以下公式的双环烷基或双环烯基基团：##STR2##从而形成双环烷基或双环烯基化合物，其中m和n是整数，其值为0至3，p是整数，其值为0至4，q是整数，其值为1至4，其中这样的双环烯基的双键位于m、n、p或q桥上；R.sub.4为氢或甲基，或与R.sub.2或R.sub.3一起形成如上所定义的环烷基、双环烷基或双环烯基，或与R.sub.5一起形成3至5个碳原子的亚甲基链，从而形成包括4至6个碳原子的环烷基；R.sub.5选自由氢、具有1至3个碳原子的直链烷基，或与R.sub.4一起形成如上定义的环烷基；R.sub.6为氢或具有1至3个碳原子的直链烷基。此外还披露了上述公式的PGE.sub.1酯类似物，仅限于其中两个R.sub.2、R.sub.3、R.sub.4和R.sub.5形成环烷基、较低烷基化环烷基、双环烷基或双环烯基的结构。前列腺素类似物在体内选择性地产生支气管扩张并减少胃分泌。还披露了制备类似物和合成类似物所需的起始材料的方法。
• Therapeutic method for inhibiting gastric secretion by administration of
  申请人：Miles Laboratories, Inc.

  公开号：US04331688A1

  公开（公告）日：1982-05-25

  Analogues of PGE.sub.1 having the structural formula, ##STR1## in which J is R-hydroxymethylene or S-hydroxymethylene; R.sub.1 is hydrogen; R.sub.2 is hydrogen or together with R.sub.4 is a methylene chain of 2 to 3 carbon atoms such that a cycloalkyl of 5 to 6 carbon atoms inclusive is formed; R.sub.3 is hydrogen or methyl, or together with R.sub.4 is a methylene or a lower alkylated methylene chain of 2 to 5 carbon atoms such that a cycloalkyl or a lower alkylated cycloalkyl of 4 to 7 carbon atoms inclusive is formed, or together with R.sub.4 is bicycloalkyl or bicycloalkenyl moiety having the formula: ##STR2## such that a bicycloalkyl or bicycloalkenyl compound is formed, wherein m and n are integers having a value from 0 to 3, p is an integer having a value from 0 to 4 and q is an integer having a value of from 1 to 4 and wherein the double bond of such bicycloalkenyl is in the m, n, p, or q bridge; R.sub.4 is hydrogen or methyl or together with R.sub.2 or R.sub.3 forms a cycloalkyl or bicycloalkyl or bicycloalkenyl as defined above, or together with R.sub.5 is a methylene chain of 3 to 5 carbon atoms such that a cycloalkyl of 4 to 6 carbon atoms inclusive is formed; R.sub.5 is selected from the group consisting of hydrogen, straight-chain alkyl having from 1 to 3 carbon atoms or together with R.sub.4 forms a cycloalkyl as defined above; and R.sub.6 is hydrogen or straight-chain alkyl having from 1 to 3 carbon atoms are disclosed. PGE.sub.1 ester analogues of the above formula, limited to the structures wherein two of R.sub.2, R.sub.3 R.sub.4 and R.sub.5 form a cycloalkyl, lower alkylated cycloalkyl, bicycloalkyl or bicycloalkenyl are also disclosed. The prostaglandin analogues selectively produce bronchodilation and decrease gastric secretion in vivo. Methods of preparing the analogues and starting materials required in the synthesis of the analogues are also disclosed.

  具有结构式 ##STR1## 的PGE.sub.1类似物，其中J为R-羟甲基或S-羟甲基；R.sub.1为氢；R.sub.2为氢或与R.sub.4一起形成2到3个碳原子的亚甲基链，从而形成5到6个碳原子的环烷基；R.sub.3为氢或甲基，或与R.sub.4一起形成2到5个碳原子的亚甲基或较低烷基化亚甲基链，从而形成4到7个碳原子的环烷基或较低烷基化环烷基，或与R.sub.4一起形成具有公式的双环烷基或双环烯基基团： ##STR2## 从而形成双环烷基或双环烯基化合物，其中m和n是具有0到3的整数值，p是具有0到4的整数值，q是具有1到4的整数值，并且此类双环烯基的双键在m、n、p或q桥上；R.sub.4为氢或甲基，或与R.sub.2或R.sub.3一起形成上述定义的环烷基或双环烷基或双环烯基，或与R.sub.5一起形成3到5个碳原子的亚甲基链，从而形成4到6个碳原子的环烷基；R.sub.5选自由由氢、具有1到3个碳原子的直链烷基或与R.sub.4一起形成上述定义的环烷基的群；R.sub.6为氢或具有1到3个碳原子的直链烷基。所述PGE.sub.1酯类似物的结构式，限于其中两个R.sub.2、R.sub.3、R.sub.4和R.sub.5形成环烷基、较低烷基化环烷基、双环烷基或双环烯基的情况也被揭示。该前列腺素类似物在体内选择性地产生支气管扩张和减少胃分泌。还揭示了制备类似物和合成所需起始材料的方法。
• US4132738A
  申请人：——

  公开号：US4132738A

  公开（公告）日：1979-01-02